News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
815,509 Results
Type
Article (74215)
Company Profile (643)
Press Release (740651)
Multimedia
Podcasts (124)
Webinars (14)
Section
Business (226515)
Career Advice (3717)
Deals (39174)
Drug Delivery (129)
Drug Development (89012)
Employer Resources (198)
FDA (17814)
Job Trends (17091)
News (386169)
Policy (38648)
Tag
Academia (2999)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (96)
Alliances (55848)
ALS (104)
Alzheimer's disease (1505)
Antibody-drug conjugate (ADC) (164)
Approvals (17769)
Artificial intelligence (307)
Autoimmune disease (29)
Automation (16)
Bankruptcy (402)
Best Places to Work (12632)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (439)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (313)
Cancer (2482)
Cardiovascular disease (210)
Career advice (3166)
Career pathing (34)
CAR-T (176)
Cell therapy (490)
Cervical cancer (22)
Clinical research (72005)
Collaboration (935)
Company closure (2)
Compensation (578)
Complete response letters (30)
COVID-19 (2868)
CRISPR (50)
C-suite (275)
Cystic fibrosis (109)
Data (2361)
Decentralized trials (2)
Denatured (41)
Depression (56)
Diabetes (302)
Diagnostics (6924)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (132)
Drug pricing (130)
Drug shortages (33)
Duchenne muscular dystrophy (104)
Earnings (93729)
Editorial (47)
Employer branding (25)
Employer resources (167)
Events (128899)
Executive appointments (788)
FDA (19242)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (826)
Gene editing (125)
Generative AI (27)
Gene therapy (362)
GLP-1 (859)
Government (5121)
Grass and pollen (6)
Guidances (150)
Healthcare (20874)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (152)
Indications (30)
Infectious disease (3031)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (58)
Intellectual property (102)
Interviews (727)
IPO (17732)
IRA (51)
Job creations (4942)
Job search strategy (2589)
Kidney cancer (11)
Labor market (47)
Layoffs (564)
Leadership (24)
Legal (9887)
Liver cancer (82)
Lung cancer (349)
Lymphoma (161)
Machine learning (9)
Management (65)
Manufacturing (363)
MASH (81)
Medical device (14623)
Medtech (14628)
Mergers & acquisitions (22010)
Metabolic disorders (806)
Multiple sclerosis (89)
NASH (23)
Neurodegenerative disease (116)
Neuropsychiatric disorders (34)
Neuroscience (2120)
NextGen: Class of 2025 (7634)
Non-profit (5080)
Now hiring (41)
Obesity (433)
Opinion (275)
Ovarian cancer (83)
Pain (105)
Pancreatic cancer (91)
Parkinson's disease (162)
Partnered (22)
Patents (258)
Patient recruitment (119)
Peanut (51)
People (63850)
Pharmaceutical (132)
Pharmacy benefit managers (22)
Phase I (22250)
Phase II (31416)
Phase III (23693)
Pipeline (1397)
Policy (180)
Postmarket research (3239)
Preclinical (9807)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (436)
Real estate (7115)
Recruiting (75)
Regulatory (26009)
Reports (58)
Research institute (2655)
Resumes & cover letters (579)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (82)
Series A (144)
Series B (94)
Service/supplier (26)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4190)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (54)
The Weekly (81)
Vaccines (822)
Venture capitalists (45)
Weight loss (306)
Women's health (38)
Worklife (20)
Date
Last 7 days (987)
Last 30 days (3184)
Last 365 days (34869)
2025 (12546)
2024 (37887)
2023 (42567)
2022 (53926)
2021 (58722)
2020 (57663)
2019 (51302)
2018 (39084)
2017 (36786)
2016 (37676)
2015 (43661)
2014 (38254)
2013 (34184)
2012 (36131)
2011 (36208)
2010 (35540)
Location
Africa (1186)
Alabama (61)
Alaska (7)
Arizona (245)
Arkansas (14)
Asia (48565)
Australia (8336)
California (6679)
Canada (2107)
China (574)
Colorado (289)
Connecticut (305)
Delaware (166)
Europe (109706)
Florida (977)
Georgia (226)
Hawaii (1)
Idaho (63)
Illinois (623)
India (30)
Indiana (342)
Iowa (12)
Japan (177)
Kansas (112)
Kentucky (28)
Louisiana (15)
Maine (70)
Maryland (991)
Massachusetts (5107)
Michigan (249)
Minnesota (430)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (69)
New Hampshire (69)
New Jersey (1878)
New Mexico (31)
New York (1876)
North Carolina (1142)
North Dakota (9)
Northern California (2877)
Ohio (224)
Oklahoma (15)
Oregon (46)
Pennsylvania (1463)
Puerto Rico (14)
Rhode Island (36)
South America (1561)
South Carolina (26)
South Dakota (1)
Southern California (2482)
Tennessee (108)
Texas (994)
United States (25436)
Utah (199)
Virginia (175)
Washington D.C. (72)
Washington State (611)
West Virginia (3)
Wisconsin (70)
815,509 Results for "wuxi pharmatech co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Manufacturing
Merck Snaps Up WuXi Biologics Facility in Ireland for $500M
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.
January 6, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
April 18, 2025
·
3 min read
Press Releases
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Completion of Sample Set for the Strategic Partnership Implemented to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
May 9, 2025
·
3 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
BIOSECURE Act
WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow
WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.
October 8, 2024
·
5 min read
·
Ben Hargreaves
Podcast
BioSpace
at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More
Cell and gene therapy investment rebounds; WuXi Biologics and other companies named in BIOSECURE Act mull options; Bayer, J&J and Pfizer’s recent layoffs; updates from the weight loss space.
October 9, 2024
·
1 min read
·
Heather McKenzie
BIOSECURE Act
WuXi Mulls Sale of Some US, European Operations: FT
The
Financial Times
reported Thursday that WuXi AppTec is looking to sell its cell and gene therapy manufacturing unit, with facilities in Philadelphia, while WuXi Biologics wants to offload some of its production sites in Europe.
October 3, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NAMSA Completes Acquisition of WuXi AppTec US Medical Device Testing Business
March 4, 2025
·
2 min read
Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs
As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit.
July 3, 2024
·
4 min read
·
Tyler Patchen
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
1 of 81,551
Next
